Glucose monitoring and arrhythmia risk in diabetes

For people with diabetes and atrial fibrillation (AF), continuous glucose monitoring (CGM) offers a detailed view of day-to-day glucose patterns. Pairing sensor traces with symptoms and rhythm recordings can reveal whether metabolic disturbances coincide with episodes that might otherwise remain unexplained.

The clinical question is important but frequently overstated. Studies link some glucose metrics with AF burden or new-onset AF, yet CGM is not an anticoagulation calculator, and evidence that reducing glucose variability prevents AF is not yet definitive. Good interpretation begins by separating association from causation.

Patients may spend long periods without noticing either a hypoglycaemic episode or an arrhythmia. In Australia, renewed interest in CGM has made glucose profiles more accessible, while mobile ECG and implanted devices provide increasingly precise estimates of AF burden. These streams of data can inform a conversation, but they do not replace clinical assessment.

This article examines the evidence linking CGM-derived measures with AF risk in diabetic patients, the practical work of establishing an arrhythmia event, and the safeguards needed to use both safely. The emphasis is on coordinated care across diabetes, cardiology and primary care, rather than on treating a sensor trace as a diagnosis.

Why diabetes and atrial fibrillation intersect

Diabetes raises the likelihood of AF through several overlapping pathways. Insulin resistance, central adiposity, inflammation and autonomic neuropathy can promote atrial remodelling, while hypertension, kidney disease and obstructive sleep apnoea add to overall cardiovascular risk.

AF itself changes cardiac output and may influence diabetes management, particularly when rate control is imperfect or physical activity becomes difficult. Conversely, glucose swings can alter autonomic tone and the electrical properties of the heart, making the timing of an arrhythmia more informative than a single HbA1c result.

This bidirectional relationship argues for shared decision-making. An endocrinologist may notice recurrent nocturnal lows, while an electrophysiologist may detect recurrent AF after ablation. Bringing the same timeline to both teams allows each clinician to assess whether metabolic change preceded the arrhythmia rather than merely coexisting with it.

What continuous glucose monitoring reveals

CGM measures interstitial glucose rather than blood glucose directly, so readings can trail rapid changes by several minutes. Compressive lows during sleep and differences between sensors and laboratory measurements also require context. Unexpected symptoms or marked disagreement with a meter should prompt confirmation according to device instructions and the patient’s clinical plan.

Time in range, commonly defined as 70–180 mg/dL (3.9–10.0 mmol/L), describes time spent within a target interval. Time below and above range, glycaemic variability and the ambulatory glucose profile reveal different aspects of control. HbA1c summarises longer-term exposure but cannot show a brief nocturnal low or a sharp post-meal excursion.

For adults with type 1 diabetes, a goal of more than 70% time in range is widely used, alongside a limit on readings below 70 mg/dL. Targets for type 2 diabetes should be individualised; a neat percentage may obscure recurrent severe hypoglycaemia, frailty or an illness that makes tighter control unsafe. These are diabetes targets, not established thresholds for AF prevention.

Glucose variability and arrhythmia signals

Nocturnal hypoglycaemia can provoke counter-regulatory hormones, adrenergic activity and changes in potassium that may increase arrhythmogenicity. Small studies using CGM or insulin pumps have linked hypoglycaemic nights with more frequent AF, including in people without diabetes, but the observations do not establish that every low causes an episode.

In people with type 2 diabetes, some observational studies associate poorer glycaemic control and greater glucose variability with incident AF or greater arrhythmia burden. Inflammation, oxidative stress, dehydration and altered autonomic function may connect hyperglycaemia to atrial substrate. However, study populations, AF ascertainment and exposure definitions vary, and residual confounding by obesity, renal function or disease severity remains.

The practical interpretation is therefore temporal rather than numerical. Does AF cluster after a low, during sustained hyperglycaemia, or after meals? Are episodes nocturnal, exercise-related or linked to missed medication? A reproducible pattern can justify targeted review; an isolated sensor spike usually cannot explain recurrent AF.

Measuring atrial fibrillation alongside glucose

CGM timestamps glucose patterns but does not diagnose AF. Pulse checks and smartwatch photoplethysmography can flag an irregular rhythm, although confirmatory ECG and clinician review are needed. Continuous ECG patches, external loop recorders and implantable monitors can quantify AF burden when symptoms are infrequent or paroxysmal.

For people with diabetes, aligning CGM data with an ECG event log can distinguish a true arrhythmic episode from a glucose-related sensation. A diary of meals, insulin, alcohol, caffeine, exercise, sleep and medication changes is essential, but it must remain manageable; automated timestamps are helpful when they can be reliably exported.

For patients with an implanted pacemaker or defibrillator, device management guidance on detection and extraction can support safe device follow-up. That expertise remains distinct from metabolic monitoring, although device electrograms can provide valuable confirmation of AF burden.

Using the data in Australian practice

Australia’s National Diabetes Services Scheme (NDSS) subsidises CGM for eligible people with type 1 diabetes and a growing group with type 2 diabetes who meet specific criteria. Access usually follows referral, enrolment and, in many cases, a consultation with a diabetes educator. Private insurance and the broader retail market also influence which devices and support services are available.

Daily life shapes the data. A Sydney commuter may manage a walk to the station and a long seated workday differently from a Melbourne cyclist during a social ride, and the same meal can produce a different glucose trace. In Brisbane, hot and humid conditions may alter hydration, food choices and activity timing, making local context more informative than a generic target.

General practitioners, diabetes educators, pharmacists and cardiologists often share information through electronic medical records, with telehealth expanding access outside metropolitan centres. Teams should agree on who reviews downloads, how quickly clinically important alerts are escalated, and when a rhythm episode needs formal electrophysiology assessment. Clear responsibility matters more than adding another dashboard.

Limits, safeguards and research gaps

CGM alerts can generate anxiety, false reassurance or alarm fatigue. Severe low readings, repeated alerts or symptomatic hyperglycaemia deserve prompt review, but routine adjustments to insulin or anticoagulants should not be made from CGM data alone. Anticoagulation decisions should follow established stroke-risk assessment, including CHA2DS2-VASc, with bleeding-risk assessment and shared decision-making; glucose variability is not an established indication.

Devices sold in Australia are regulated by the Therapeutic Goods Administration, and clinicians should verify the intended indication, sensor accuracy and data-sharing functions. The Privacy Act 1988 and Australian Privacy Principles apply to many organisations handling personal health information. Consent should explain which cloud platform receives data, who can access it and how long records are retained.

The Australian market includes global manufacturers and locally supported services, making interoperability a genuine concern. Researchers should preserve common terminology, record sensor type and wear time, and report missing data. Trials need simultaneous rhythm monitoring, prespecified glucose metrics and outcomes such as AF burden, stroke and hypoglycaemia, rather than relying on self-reported palpitations alone. Clinicians and trainees can extend their background with the journal’s supplementary reading links, while checking the relevance and quality of any material they consult.

Building a practical care pathway

Start with the reason for monitoring. CGM may be selected for diabetes management, recurrent symptomatic episodes or research; AF risk alone is not currently an established indication. Agree on the clinical question, the minimum duration of wear and the success criterion. A month can characterise glucose patterns, while symptom-triggered rhythm recording may be more useful for infrequent AF.

At review, inspect the ambulatory glucose profile alongside clinically important low and high excursions, then overlay confirmed AF episodes. Ask whether the same day includes missed meals, alcohol, infection, poor sleep, vigorous exercise or a medication change. A short, accurate timeline is more useful than a large collection of unvalidated correlations.

When AF is confirmed, follow established rhythm and stroke-prevention pathways, with attention to blood pressure, lipids, weight, kidney function and sleep apnoea. Diabetes treatment should be individualised to reduce hypoglycaemia and meet overall metabolic goals. An electrophysiology referral is appropriate for troublesome symptoms, uncertain diagnosis, recurrent episodes or consideration of catheter ablation.

The next clinical review is a practical starting point. Invite patients to bring CGM downloads and rhythm documentation, maintain a concise diary of meals, medication, alcohol, exercise and symptoms, and agree on what will trigger an ECG or electrophysiology referral. Severe symptomatic hypoglycaemia requires urgent treatment under the person’s existing emergency plan.

Australian investigators, diabetes services and electrophysiology teams can turn better monitoring into better evidence by standardising CGM and AF-burden reporting, linking de-identified, consent-based datasets and testing interventions against outcomes such as recurrent AF, stroke and severe hypoglycaemia.